Business
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference
BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced
About this update from Edgewise Therapeutics, Inc.
[{"type":"text","content":"BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The Company will host a lunch forum with experts presenting Becker natural history data and discussing the need for community and definition of care. New sevasemten data in Becker will also be presented at the conference including from the MESA open-label extension trial. The conference will take place at the Hilton Orlando in Orlando, Fla., from March 8–11, 2026.\n \n \n \n \n \n \n \nDetails of the Edgewise forum and scientific posters at MDA:Edgewise Lunch Forum Highlighting Becker Natural History, Community Progress, and Multi-Disciplinary Care with Neuromuscular Disease Experts Date: Monday, March 9, 2026, at noon ETTitle: Elevating Becker Outcomes: Unlocking New Insights, Mobilizing Communities, and Redefining Care Presenters: Matthew Wicklund, M.D., FAAN, Professor of Neurology, Vice Chair for Research, Department of Neurology, UT Health San AntonioAbby Bronson, M.B.A., Vice President, Patient Advocacy and External Innovation, EdgewiseAmit Sachdev, M.D., M.S., Associate Chief Medical Officer, MSU Healthcare, Medical Director, Department of Neurology and Assistant Professor, Neuromuscular Medicine, Michigan State UniversityModerator: Roxana Donisa Dreghici, M.D., Vice President, Clinical Development, EdgewiseOnly conference attendees can register for the forum.Scientific PostersTitle: Long-term stabilization of function in Becker: Sevasemten prevented functional decline up to 3.5 years in MESA open-label extension (477LB)Presenter: Craig M. McDonald, M.D., Distinguished Professor and Chair at the UC Davis Health Department of Physical Medicine and Rehabilitation, and a Principal Investigator in CANYON and GRAND CANYONDate: Tuesday, March 10, 2026Title: Effects of sevasemten on LVEF and NT-proBNP in adults with Becker muscular dystrophy in CANYON (470LB) Presenter: Ben Barthel, Ph.D., Edgewise Date: Monday, March 9, 2026Title: Patient-focused drug development: Understanding the patient experience and meaningful treatment outcomes in Becker muscular dystrophy via interviews (8S)Presenter: Abby Bronson, EdgewiseDate: Sunday, March 8, 2026Title: Female carriers of BMD an...